Literature DB >> 24619267

Frequency of Pneumocystis jirovecii in sputum from HIV and TB patients in Namibia.

Vincent Nowaseb1, Esegiel Gaeb, Marcin G Fraczek, Malcolm D Richardson, David W Denning.   

Abstract

INTRODUCTION: The opportunistic fungus Pneumocystis jirovecii causes Pneumocystis pneumonia (PcP), which is a life-threatening infection in HIV/AIDS patients. The seemingly low prevalence of P. jirovecii pneumonia in sub-Saharan Africa has been a matter of great debate because many HIV/AIDS patients reside in this region. The lack of suitable diagnostic practices in this resource limited-region has been added to the uncertainty of PcP prevalence. Only a few studies have evaluated the utility of easily obtainable samples such as expectorated sputum for diagnosis of PcP. Thus, the aim of the current study was to evaluate the effectiveness of expectorated sputum for the routine diagnosis of PcP in a resource-limited sub-Saharan African setting.
METHODOLOGY: Randomly collected sputum samples were analysed by microscopy after Grocott's methenamine silver (GMS) stain staining and by qPCR to determine the minimum frequency of detectable P. jirovecii.
RESULTS: A total of 475 samples were analysed. Twenty five (5.3%) samples were positive for P. jirovecii, i.e., 17 (3.6%) using both qPCR and GMS staining and eight (1.7%) using qPCR only. P. jirovecii was present in 8/150 (5.3%) HIV-positive and tuberculosis (TB) smear-negative patients, and in 12/227 (5.3%) TB smear-negative patients with an unknown HIV status. The minimum frequency of PcP was 3.6% in Namibian HIV and TB patients, while the actual frequency is likely to be 5.3%.
CONCLUSION: This study demonstrated that expectorated sputum can be used routinely for the diagnosis of PcP by GMS, although qPCR is more sensitive, and it requires less time and skill.

Entities:  

Mesh:

Year:  2014        PMID: 24619267     DOI: 10.3855/jidc.3864

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  8 in total

Review 1.  A Molecular Window into the Biology and Epidemiology of Pneumocystis spp.

Authors:  Liang Ma; Ousmane H Cissé; Joseph A Kovacs
Journal:  Clin Microbiol Rev       Date:  2018-06-13       Impact factor: 26.132

Review 2.  Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized.

Authors:  David W Denning
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2016-12-05       Impact factor: 6.237

Review 3.  Delivering on Antimicrobial Resistance Agenda Not Possible without Improving Fungal Diagnostic Capabilities.

Authors:  David W Denning; David S Perlin; Eavan G Muldoon; Arnaldo Lopes Colombo; Arunaloke Chakrabarti; Malcolm D Richardson; Tania C Sorrell
Journal:  Emerg Infect Dis       Date:  2017-02-15       Impact factor: 6.883

4.  Estimated Burden of Fungal Infections in Namibia.

Authors:  Cara M Dunaiski; David W Denning
Journal:  J Fungi (Basel)       Date:  2019-08-16

Review 5.  Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options.

Authors:  Alimuddin Zumla; Ziad A Memish; Markus Maeurer; Matthew Bates; Peter Mwaba; Jaffar A Al-Tawfiq; David W Denning; Frederick G Hayden; David S Hui
Journal:  Lancet Infect Dis       Date:  2014-09-01       Impact factor: 25.071

6.  Epidemiology of fungal diseases in Africa: A review of diagnostic drivers.

Authors:  Felix Bongomin; Samuel Adetona Fayemiwo
Journal:  Curr Med Mycol       Date:  2021-03

7.  The burden of serious fungal infections in Azerbaijan.

Authors:  Ravil M Huseynov; Samir S Javadov; Ali Osmanov; Shahin Khasiyev; Samira R Valiyeva; Esmira Almammadova; David W Denning
Journal:  Ther Adv Infect Dis       Date:  2021-09-03

8.  Evaluation of Three Different Laboratory Methods for Identification of Pneumocystis jirovecii Pneumonia (PCP) among HIV Positive Asymptomatic Prisoners.

Authors:  Shohreh Azimi; Azar Sabokbar; Amir Bairami; Mohammad Javad Gharavi
Journal:  Iran J Parasitol       Date:  2019 Apr-Jun       Impact factor: 1.012

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.